CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Javelin Pharmaceuticals, Inc. v. Mylan Laboratories Limited

1:16-cv-00224

Overview

Case Number 1:16-cv-00224
Filing Date 2016-04-04
Status Terminated
Termination Date 2017-12-18
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mylan Laboratories Limited NPE (University / Research)

Represented By

4 Attorneys Listed

Mitchell G. Stockwell

Email: mstockwell@kilpatricktownsend.com

David Clay Holloway

Email: cholloway@kilpatricktownsend.com

Alyson L. Wooten

Email: awooten@kilpatricktownsend.com

Mary Matterer

ADDRESS EXPIRED / UNKNOWN

Tel: +1 (302) 888-6800
Fax: +1 (302) 571-1750

ADDRESS EXPIRED / UNKNOWN, (302) 888-6800

Mylan Pharmaceuticals Inc. Operating Company

Represented By

4 Attorneys Listed

Mitchell G. Stockwell

Email: mstockwell@kilpatricktownsend.com

David Clay Holloway

Email: cholloway@kilpatricktownsend.com

Alyson L. Wooten

Email: awooten@kilpatricktownsend.com

Mary Matterer

ADDRESS EXPIRED / UNKNOWN

Tel: +1 (302) 888-6800
Fax: +1 (302) 571-1750

ADDRESS EXPIRED / UNKNOWN, (302) 888-6800

Plaintiff

Javelin Pharmaceuticals, Inc. Operating Company

Represented By

5 Attorneys Listed

Arthur G. Connolly , III

Connolly Gallagher LLP

Tel: +1 (302) 757-7300

1201 North Market Street, 20th Floor, Wilmington, DE 19801

Mary I. Akhimien

Connolly Gallagher LLP

Tel: +1 (302) 252-3645
Fax: +1 (302) 757-7271

1201 North Market Street, 20th Floor, Wilmington, DE 19801

Alison Hanstead

Email: ahanstead@whitecase.com

Jeffrey J. Oelke

Email: joelke@fenwick.com

Ryan Patrick Newell

Connolly Gallagher LLP

Tel: +1 (302) 888-6434

1201 North Market Street, 20th Floor, Wilmington, DE 19801

Janssen Pharmaceutica N.V. NPE (Individual / Inventor)

Represented By

5 Attorneys Listed

Claire K. Comfort

Email: claire.comfort@weil.com

Audrey Maness

Email: audrey.maness@weil.com

Elizabeth S. Weiswasser

Email: elizabeth.weiswasser@weil.com

Brian P. Egan

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9454

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Counter Claimant

Hospira, Inc. Operating Company

Represented By

5 Attorneys Listed

Arthur G. Connolly , III

Connolly Gallagher LLP

Tel: +1 (302) 757-7300

1201 North Market Street, 20th Floor, Wilmington, DE 19801

Mary I. Akhimien

Connolly Gallagher LLP

Tel: +1 (302) 252-3645
Fax: +1 (302) 757-7271

1201 North Market Street, 20th Floor, Wilmington, DE 19801

Alison Hanstead

Email: ahanstead@whitecase.com

Jeffrey J. Oelke

Email: joelke@fenwick.com

Ryan Patrick Newell

Connolly Gallagher LLP

Tel: +1 (302) 888-6434

1201 North Market Street, 20th Floor, Wilmington, DE 19801

Mylan Inc. Operating Company

Represented By

5 Attorneys Listed

Courtney S. Dabbiere

Email: cdabbiere@kilpatricktownsend.com

Mitchell G. Stockwell

Email: mstockwell@kilpatricktownsend.com

David Clay Holloway

Email: cholloway@kilpatricktownsend.com

Alyson L. Wooten

Email: awooten@kilpatricktownsend.com

Mary Matterer

ADDRESS EXPIRED / UNKNOWN

Tel: +1 (302) 888-6800
Fax: +1 (302) 571-1750

ADDRESS EXPIRED / UNKNOWN, (302) 888-6800

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 2 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 1 proceeding
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (2): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (1 found):
U.S. Courts: 1
U.S. District Court 2016-06-29
1:16-cv-00554

Janssen Pharmaceutica N.V. v. Xellia Pharmaceuticals ApS

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6407079
Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
Filed: 1988-10-31
Issued: 2002-06-18
Expired (Term Ended)
Expires: 2008-10-31
US8946292
Formulations of low dose diclofenac and beta-cyclodextrin
Filed: 2011-05-12
Issued: 2015-02-03
Active (4.5 yrs remaining)
Expires: 2031-05-12

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

36

Dispositive

14

Granted

0

Denied

2

Pending / Review

27

Motions by Category

Claim Construction / Markman Filing 14 Procedural / Extension Motion 8 Motion to Dismiss 14

Key Dispositive Motions & Rulings

Motion to Dismiss Denied
MEMORANDUM ORDER re 58 MOTION to Dismiss for Improper Venue under Fed. R. Civ. P. 12(b)(3) or, in the alternative, Motion to Transfer Venue filed by Mylan Labor...
Entry #102 • 2017-12-01 Document →
Motion to Dismiss Pending / Under Review
REDACTED VERSION of 73 Letter, to The Honorable Leonard P. Stark from Mary B. Matterer responding to the Court's Order requesting further briefing on Mylan's Mo...
Entry #81 • 2017-09-27 Document →
Motion to Dismiss Pending / Under Review
[SEALED] Letter to The Honorable Leonard P. Stark from Mary B. Matterer regarding Mylan's opening letter brief responding the Court's Order requesting further b...
Entry #73 • 2017-09-20 Document →
Motion to Dismiss Pending / Under Review
REDACTED VERSION of 66 Reply Brief in support of Defendants' Motion to Dismiss under Rule 12(b)(3) for Improper Venue or, in the alternative, Motion to Transfer...
Entry #71 • 2017-09-14 Document →
Motion to Dismiss Pending / Under Review
REDACTED VERSION of 67 Declaration of Keith Meckstroth in support of Defendants' Reply Brief regarding Motion to Dismiss under Rule 12(b)(3) for Improper Venue ...
Entry #72 • 2017-09-14 Document →
Motion to Dismiss Pending / Under Review
[SEALED] REPLY BRIEF re 58 MOTION to Dismiss for Improper Venue under Fed. R. Civ. P. 12(b)(3) or, in the alternative, Motion to Transfer Venue filed by Mylan I...
Entry #66 • 2017-09-07 Document →

Docket Entries

(171 total)
Pleading / Complaint

COMPLAINT filed against Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1906414.) - filed by Javelin Pharmaceuticals, Inc., Janssen Pharmaceutica N.V., Hospira, Inc. (Attachments: # 1 Exhibit A & B, # 2 Civil Cover Sheet)(klc) (Entered: 04/04/2016)

Entry #1 • 2016-04-04
1
Pleading / Complaint

COMPLAINT filed against Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1906414.) - filed by Javelin Pharmaceuticals, Inc., Janssen Pharmaceutica N.V., Hospira, Inc. (Attachments: # 1 Exhibit A & B, # 2 Civil Cover Sheet)(klc) (Entered: 04/04/2016)

Entry #1 • 2016-04-04
2
Pleading / Complaint

COMPLAINT filed against Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1906414.) - filed by Javelin Pharmaceuticals, Inc., Janssen Pharmaceutica N.V., Hospira, Inc. (Attachments: # 1 Exhibit A & B, # 2 Civil Cover Sheet)(klc) (Entered: 04/04/2016)

Entry #1 • 2016-04-04
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (klc) (Entered: 04/04/2016)

Entry #2 • 2016-04-04
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: On or about 2/23/2016. Date of Expiration of Patent: ** See Attached ANDA Form.Thirty Month Stay Deadline: On or About 8/23/2018. (klc) (Entered: 04/04/2016)

Entry #3 • 2016-04-04
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc